Julie Harris-Wai, PhD, MPH

Assistant Adjunct Professor


Dr. Harris-Wai’s research focuses on examining the social and ethical factors influencing how and why genomic technologies are translated from the research setting into clinical care and the impact these technologies have on health disparities and underserved communities. The goal of her work is to identify methods for incorporating community and stakeholder perspectives into policy decision-making to improve the appropriate translation of research into clinical and public health programs. Dr. Harris-Wai is the Associate Director of the Kaiser Permanente/UCSF Center for Excellence in Research on Translational Genomics and Ethics (CT2G). She is currently working on an R21 from the Agency for Healthcare Research and Quality to use deliberative community engagement methods to inform policy decisions about the future of California’s Newborn Screening Program.

Awarded Grants:
1. Engaging Diverse Communities to Inform California’s Newborn Screening Policies, Principal Investigator; Agency for Healthcare Research and Quality (AHRQ), 2014-2016

2. Center for Transdisciplinary ELSI Research in Translational Genomics (CT2G), Co-Investigator; National Human Genome Research Institute (NHGRI), 2013-2016

3. Alameda County Network Project to Reduce Cancer Disparities, Co-Investigator; National Cancer Institute (NCI), 2010-2015



Bowen DJ, Hay JL, Harris-Wai JN, Meischke H, Burke W. All in the family? Communication of cancer survivors with their families. Fam Cancer. 2017 Oct; 16(4):597-603.
Wolf SM, Amendola LM, Berg JS, Chung WK, Clayton EW, Green RC, Harris-Wai J, Henderson GE, Jarvik GP, Koenig BA, Lehmann LS, McGuire AL, O'Rourke P, Somkin C, Wilfond BS, Burke W. Navigating the research-clinical interface in genomic medicine: analysis from the CSER Consortium. Genet Med. 2017 Aug 31.
Joseph G, Chen F, Harris-Wai J, Puck JM, Young C, Koenig BA. Parental Views on Expanded Newborn Screening Using Whole-Genome Sequencing. Pediatrics. 2016 Jan; 137 Suppl 1:S36-46.
Lemke AA, Harris-Wai JN. Stakeholder engagement in policy development: challenges and opportunities for human genomics. Genet Med. 2015 Dec; 17(12):949-57.
Bowen DJ, Burke W, Hay JL, Meischke H, Harris JN. Effects of web-based intervention on risk reduction behaviors in melanoma survivors. J Cancer Surviv. 2015 Jun; 9(2):279-86.
Harris JN, Liljestrand P, Alexander GL, Goddard KA, Kauffman T, Kolevska T, McCarty C, O'Neill S, Pawloski P, Rahm A, Williams A, Somkin CP. Oncologists' attitudes toward KRAS testing: a multisite study. Cancer Med. 2013 Dec; 2(6):881-8.
Cross DS, Rahm AK, Kauffman TL, Webster J, Le AQ, Spencer Feigelson H, Alexander G, Meier P, Onitilo AA, Pawloski PA, Williams AE, Honda S, Daida Y, McCarty CA, Goddard KA. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013 Dec; 15(12):933-40.
Webster J, Kauffman TL, Feigelson HS, Pawloski PA, Onitilo AA, Potosky AL, Cross D, Meier PR, Mirabedi AS, Delate T, Daida Y, Williams AE, Alexander GL, McCarty CA, Honda S, Kushi LH, Goddard KA. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):91-101.
Bowen DJ, Hay JL, Mayer J, Kuniyuki A, Meischke H, Harris J, Asgari M, Shoveller J, Press N, Burke W. Predictors of recruited melanoma families into a behavioral intervention project. Contemp Clin Trials. 2012 Jan; 33(1):85-92.
Boehmer U, Harris J, Bowen DJ, Schroy PC. Surveillance after colorectal cancer diagnosis in a safety net hospital. J Health Care Poor Underserved. 2010 Nov; 21(4):1138-51.
Harris JN, Hay J, Kuniyuki A, Asgari MM, Press N, Bowen DJ. Using a family systems approach to investigate cancer risk communication within melanoma families. Psychooncology. 2010 Oct; 19(10):1102-11.
Bowen DJ, Harris J, Jorgensen CM, Myers MF, Kuniyuki A. Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign. Public Health Genomics. 2010; 13(3):131-42.
Harris JN, Bowen DJ, Kuniyuki A, McIntosh L, FitzGerald LM, Ostrander EA, Stanford JL. Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med. 2009 May; 11(5):344-55.
Harris J, Bowen DJ, Badr H, Hannon P, Hay J, Regan Sterba K. Family communication during the cancer experience. J Health Commun. 2009; 14 Suppl 1:76-84.
Hay J, Harris JN, Waters EA, Clayton MF, Ellington L, Abernethy AD, Prayor-Patterson H. Personal communication in primary and secondary cancer prevention: evolving discussions, emerging challenges. J Health Commun. 2009; 14 Suppl 1:18-29.
James RD, Yu JH, Henrikson NB, Bowen DJ, Fullerton SM. Strategies and stakeholders: minority recruitment in cancer genetics research. Community Genet. 2008; 11(4):241-9.
Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007 Oct; 9(10):695-704.
Henrikson NB, Harris JN, Bowen DJ. Predictors of self-referral into a cancer genetics registry. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1387-92.
+1 415 476-5362
3333 California Street, Rm 360B
UCSF Box 0646
San Francisco, CA 94118
United States